Jubilant DraxImage is dedicated to providing radiopharmaceuticals for the diagnosis and treatment of a variety of diseases. We invite you to learn more about these areas and how our products are used by healthcare professionals to care for their patients.
Radioactive iodine (RAI) ablation is the standard of care backed by decades of clinical success for the treatment of DTC.1 Consider these data:
A recent study demonstrated that low-risk patients over the age of 45 who receive a dose of at least 54 mCi have a significantly lower 15-year mortality rate (P=.002) and a higher rate of successful ablation than those patients receiving a lower dose (see Figure 2)3
* Low-risk DTC classified as patients with pT1b-T2 tumors without lymph node or distant metastases.
†After complete remission.